Fabio Bagnoli is a Senior Scientific Director at GSK, leading a multidisciplinary research team based in Siena, Italy, and Upper Providence, USA. His team focuses on the discovery and development of monoclonal antibodies (mAbs) and small molecules targeting bacterial pathogens.

Fabio’s research has been instrumental in the development of numerous vaccine candidates, with outcomes that include several patents and publications in high-impact peer-reviewed journals, addressing a wide range of human pathogens.

He has spearheaded innovative approaches in research and development, including:

1.Integrated clinical study design evaluating safety, immunogenicity, and efficacy for a S. aureus vaccine in a first time in human Ph I-II clinical trial.

2.Human organotypic models for studying mechanism of action of mAbs and vaccines.

3.Advanced vaccine formulations for creating formulations that stimulate diverse protective mechanisms.

In addition to his scientific achievements, Fabio has served as editor for several publications and has successfully coordinated collaborative efforts between industry and academia.

Fabio holds a Ph.D. in Molecular and Cellular Microbiology from the University of Padova and completed his postdoctoral research at Stanford University under the mentorship of Dr. Manuel Amieva and Dr. Stanley Falkow.

Dr. Fabio Bagnoli